Treatment with a Ginkgo biloba extract, EGb 761, inhibits excitotoxicity in an animal model of spinocerebellar ataxia type 17

Ding Siang Huang, Hsuan Yuan Lin, Guey Jen Lee-Chen, Hsiu Mei Hsieh, Chung-Hsin Wu, Jung Yaw Lin

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

Spinocerebellar ataxia type 17 (SCA 17) is a polyglutamine disease caused by the expansion of CAG/CAA repeats in the TATA box-binding protein (TBP) gene. The Ginkgo biloba extract, EGb 761, contains flavonoids and terpenoids with a potential use for the treatment of neurodegenerative diseases such as Alzheimer’s and Parkinson’s diseases. The neuroprotective effects of EGb 761 are obvious, but whether the EGb 761 has therapeutic effects in SCA 17 is still unclear. To manage our issues, we have generated TBP/79Q-expressing SH-SY5Y cells and SCA 17 transgenic mice with the mutant hTBP gene. In in vitro experiment, we observed that the EGb 761 treatment decreased the amount of sodium dodecyl sulfate-insoluble proteins in the TBP/79Q-expressing SH-SY5Y cells. We further found that the EGb 761 treatment could inhibit excitotoxicity and calcium influx and reduce the expression of apoptotic markers in glutamate-treated SH-SY5Y neuroblastoma cells. In in vivo experiment, we observed that the EGb 761 treatment (100 mg/kg intraperitoneal injection per day) could relieve the motor deficiencies of the SCA 17 transgenic mice. Our findings provide evidence that the EGb 761 treatment can be a remedy for SCA 17 via suppressing excitotoxicity and apoptosis in SCA 17 cell and animal models. Therefore, we suggest that EGb 761 may be a potential therapeutic agent for treating SCA 17.

Original languageEnglish
Pages (from-to)723-731
Number of pages9
JournalDrug Design, Development and Therapy
Volume10
DOIs
Publication statusPublished - 2016 Feb 18

Fingerprint

Animal Models
TATA-Box Binding Protein
Therapeutics
Transgenic Mice
Spinocerebellar Ataxia 17
Ginkgo biloba extract 761
Terpenes
Neuroprotective Agents
Therapeutic Uses
Intraperitoneal Injections
Neuroblastoma
Flavonoids
Sodium Dodecyl Sulfate
Neurodegenerative Diseases
Genes
Parkinson Disease
Glutamic Acid
Alzheimer Disease
Apoptosis
Calcium

Keywords

  • Apoptosis
  • EGb 761
  • Excitotoxicity
  • PolyQ diseases
  • Spinocerebellar ataxia type 17

ASJC Scopus subject areas

  • Pharmacology
  • Pharmaceutical Science
  • Drug Discovery

Cite this

Treatment with a Ginkgo biloba extract, EGb 761, inhibits excitotoxicity in an animal model of spinocerebellar ataxia type 17. / Huang, Ding Siang; Lin, Hsuan Yuan; Lee-Chen, Guey Jen; Hsieh, Hsiu Mei; Wu, Chung-Hsin; Lin, Jung Yaw.

In: Drug Design, Development and Therapy, Vol. 10, 18.02.2016, p. 723-731.

Research output: Contribution to journalArticle

@article{6b7bd8c063684059a6fdbdf179ec65f2,
title = "Treatment with a Ginkgo biloba extract, EGb 761, inhibits excitotoxicity in an animal model of spinocerebellar ataxia type 17",
abstract = "Spinocerebellar ataxia type 17 (SCA 17) is a polyglutamine disease caused by the expansion of CAG/CAA repeats in the TATA box-binding protein (TBP) gene. The Ginkgo biloba extract, EGb 761, contains flavonoids and terpenoids with a potential use for the treatment of neurodegenerative diseases such as Alzheimer’s and Parkinson’s diseases. The neuroprotective effects of EGb 761 are obvious, but whether the EGb 761 has therapeutic effects in SCA 17 is still unclear. To manage our issues, we have generated TBP/79Q-expressing SH-SY5Y cells and SCA 17 transgenic mice with the mutant hTBP gene. In in vitro experiment, we observed that the EGb 761 treatment decreased the amount of sodium dodecyl sulfate-insoluble proteins in the TBP/79Q-expressing SH-SY5Y cells. We further found that the EGb 761 treatment could inhibit excitotoxicity and calcium influx and reduce the expression of apoptotic markers in glutamate-treated SH-SY5Y neuroblastoma cells. In in vivo experiment, we observed that the EGb 761 treatment (100 mg/kg intraperitoneal injection per day) could relieve the motor deficiencies of the SCA 17 transgenic mice. Our findings provide evidence that the EGb 761 treatment can be a remedy for SCA 17 via suppressing excitotoxicity and apoptosis in SCA 17 cell and animal models. Therefore, we suggest that EGb 761 may be a potential therapeutic agent for treating SCA 17.",
keywords = "Apoptosis, EGb 761, Excitotoxicity, PolyQ diseases, Spinocerebellar ataxia type 17",
author = "Huang, {Ding Siang} and Lin, {Hsuan Yuan} and Lee-Chen, {Guey Jen} and Hsieh, {Hsiu Mei} and Chung-Hsin Wu and Lin, {Jung Yaw}",
year = "2016",
month = "2",
day = "18",
doi = "10.2147/DDDT.S98156",
language = "English",
volume = "10",
pages = "723--731",
journal = "Drug Design, Development and Therapy",
issn = "1177-8881",
publisher = "Dove Medical Press Ltd.",

}

TY - JOUR

T1 - Treatment with a Ginkgo biloba extract, EGb 761, inhibits excitotoxicity in an animal model of spinocerebellar ataxia type 17

AU - Huang, Ding Siang

AU - Lin, Hsuan Yuan

AU - Lee-Chen, Guey Jen

AU - Hsieh, Hsiu Mei

AU - Wu, Chung-Hsin

AU - Lin, Jung Yaw

PY - 2016/2/18

Y1 - 2016/2/18

N2 - Spinocerebellar ataxia type 17 (SCA 17) is a polyglutamine disease caused by the expansion of CAG/CAA repeats in the TATA box-binding protein (TBP) gene. The Ginkgo biloba extract, EGb 761, contains flavonoids and terpenoids with a potential use for the treatment of neurodegenerative diseases such as Alzheimer’s and Parkinson’s diseases. The neuroprotective effects of EGb 761 are obvious, but whether the EGb 761 has therapeutic effects in SCA 17 is still unclear. To manage our issues, we have generated TBP/79Q-expressing SH-SY5Y cells and SCA 17 transgenic mice with the mutant hTBP gene. In in vitro experiment, we observed that the EGb 761 treatment decreased the amount of sodium dodecyl sulfate-insoluble proteins in the TBP/79Q-expressing SH-SY5Y cells. We further found that the EGb 761 treatment could inhibit excitotoxicity and calcium influx and reduce the expression of apoptotic markers in glutamate-treated SH-SY5Y neuroblastoma cells. In in vivo experiment, we observed that the EGb 761 treatment (100 mg/kg intraperitoneal injection per day) could relieve the motor deficiencies of the SCA 17 transgenic mice. Our findings provide evidence that the EGb 761 treatment can be a remedy for SCA 17 via suppressing excitotoxicity and apoptosis in SCA 17 cell and animal models. Therefore, we suggest that EGb 761 may be a potential therapeutic agent for treating SCA 17.

AB - Spinocerebellar ataxia type 17 (SCA 17) is a polyglutamine disease caused by the expansion of CAG/CAA repeats in the TATA box-binding protein (TBP) gene. The Ginkgo biloba extract, EGb 761, contains flavonoids and terpenoids with a potential use for the treatment of neurodegenerative diseases such as Alzheimer’s and Parkinson’s diseases. The neuroprotective effects of EGb 761 are obvious, but whether the EGb 761 has therapeutic effects in SCA 17 is still unclear. To manage our issues, we have generated TBP/79Q-expressing SH-SY5Y cells and SCA 17 transgenic mice with the mutant hTBP gene. In in vitro experiment, we observed that the EGb 761 treatment decreased the amount of sodium dodecyl sulfate-insoluble proteins in the TBP/79Q-expressing SH-SY5Y cells. We further found that the EGb 761 treatment could inhibit excitotoxicity and calcium influx and reduce the expression of apoptotic markers in glutamate-treated SH-SY5Y neuroblastoma cells. In in vivo experiment, we observed that the EGb 761 treatment (100 mg/kg intraperitoneal injection per day) could relieve the motor deficiencies of the SCA 17 transgenic mice. Our findings provide evidence that the EGb 761 treatment can be a remedy for SCA 17 via suppressing excitotoxicity and apoptosis in SCA 17 cell and animal models. Therefore, we suggest that EGb 761 may be a potential therapeutic agent for treating SCA 17.

KW - Apoptosis

KW - EGb 761

KW - Excitotoxicity

KW - PolyQ diseases

KW - Spinocerebellar ataxia type 17

UR - http://www.scopus.com/inward/record.url?scp=84959457314&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84959457314&partnerID=8YFLogxK

U2 - 10.2147/DDDT.S98156

DO - 10.2147/DDDT.S98156

M3 - Article

VL - 10

SP - 723

EP - 731

JO - Drug Design, Development and Therapy

JF - Drug Design, Development and Therapy

SN - 1177-8881

ER -